124 / 140
Guía OncoSur de sarcomas de partes blandas
124
>
21. Van der Graaf WT, Blay JY, Chawla SP, at al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a
randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
22. Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tis-
sue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. October 14, 2016.
http://dx.doi.org/10.1016/S1470-2045(16)30507-1.
23. Valverde CM, Martín Broto J, López-Martín JA, et al. Phase II clinical trial evaluating the activity and tolera-
bility of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sar-
coma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study. J Clin Oncol 2016;34(Suppl;
abstr 11039).
24. Conyers R, Sophie Young S, Thomas DM. Liposarcoma: Molecular Genetics and Therapeutics. Hindawi Pub-
lishing Corporation Sarcoma Volume 2011, Article ID 483154.
25. Lapenna S, GiordanoA. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Dis 2009;8(7):547-66.
26. Benson C, White J, de Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibi-
tor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer
2007;96(1):29-37.
27. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in pa-
tients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol
2013;31(16):2024-8.
28. De Weger V, Lolkema MP, Dickson M, et al. A first-in-human (FIH) safety and pharmacological study of
SAR405838, a novel HDM2 antagonist, in patients with solid malignancies. Eur J Cancer 2014;50:121-2.
29. Ray-Coquard I, Blay J, ItalianoA, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients
with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mecha-
nism study. Lancet Oncol 2012;13:1133-40.
Leiomiosarcoma
30. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone ver- sus ifosfamide
plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol
1993;11:1269-75.
31. Sleijfer S, Seynaeve C, Verweij J. Using single agent therapy in adult patients with advanced soft tissue sarco-
mas can still be considered standard. Oncologist 2005;10:833-41.
32. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl tria-
zenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32.
33. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for
first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet
Oncol 2014;15:415-23
34. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus
versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst
1991;83:926-32.
35. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for meta-
static soft tissue sarcomas. J Clin Oncol 1987;5:840-50.
36. Svancárová L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study
of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:556-9.
37. Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas
(E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003;15:1669-73.
38. Hensley M, Maki R, Venkatraman E, et al. Gemcitabine and Docetaxel in Patients With Unresectable Leio-
myosarcoma: Results of a Phase II Trial. J Clin Oncol 2002;20(2):2824-31.
39. Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients
with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007;109:1863-9.
40. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyo-
sarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824-31.
41. Duffaud F, Bui BN, Penel N, et al. A FNCLCC French Sarcoma Group-GETO multicenter randomized phase
II study of gemcitabine versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosar-
coma. J Clin Oncol 2008;26:Abstr 10511.